Search

everythinglearnresearchcommunity

for

Search:↓

A 35-year-old shared a 2-month update on their hair transplant of 3153 grafts, noting redness, itching, and some pimples, while using finasteride for over 12 years to maintain hair. Users discussed the effectiveness and timing of starting finasteride, with some suggesting consulting a doctor for young individuals considering the treatment.

A user shared their 1-year crown transformation after a second hair transplant with 4000 grafts, using finasteride, minoxidil, and vitamins. Another user commented that while the crown has filled in, they expected more coverage from 4000 grafts and suggested a possible shedding phase.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

The user had a hair transplant in Toronto to restore their hairline and crown, using 2400 grafts in the first procedure and is happy with the results. They are using Minoxidil and finasteride, and note that their hair is thinner on the back and sides due to graft removal.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The potential of verteporfin to heal wounds without scarring; however, despite its promising preclinical trials and coverage from a major media outlet, there is still no official clinical trial result and the drug has only garnered attention from hair loss communities.

The user is using a 5% minoxidil solution with low propylene glycol and 1 mg of oral finasteride daily but is still experiencing hair shedding, especially at the temples and front. They are concerned about absorption issues and considering adding tretinoin to improve results.

The user is using a topical solution with finasteride, minoxidil, and other ingredients, along with a red light laser cap and dermapen, to address hair thinning. They are considering a hair transplant but are advised to try dutasteride and oral minoxidil for 12 to 18 months before deciding.

A user shared progress pictures of their FUT hair transplant in Korea, showing results one year post-op. The conversation highlights the density of the hair, the quality of Korean hair treatments, and mentions treatments like Minoxidil, finasteride, and Dutasteride.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.

The conversation is about a user's progress in treating diffuse hair thinning using a topical regimen including finasteride, minoxidil, ketoconazole, microneedling, saw palmetto, collagen, and vitamins, along with lifestyle changes. The user plans to switch from topical to oral finasteride for potentially better results.

The user is concerned about having a straight, low hairline after a hair transplant and is unable to take finasteride due to high estrogen and prolactin levels. They have used minoxidil with limited success and are considering further transplants to lower the hairline, while others suggest the risks of using up donor hair too quickly.

The user started oral minoxidil and finasteride two months after a hair transplant and plans to switch to dutasteride, using Nizoral and Mossi shampoos. They are considering a second transplant in Tijuana and using hair fibers and mousse for styling while waiting for medication effects.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user experienced significant hair regrowth using topical finasteride/minoxidil and oral minoxidil/dutasteride, with some mild side effects that diminished over time. They plan to add microneedling to their regimen and have seen hair shedding cycles every six months, followed by thicker regrowth.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

User shows temple area progress after hair transplant, using DUT every other day and oral Min 2.5 daily. Another user asks about number of grafts and cost.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

The use of PRP to treat hair loss and its potential effectiveness when combined with 5 alpha reductase blockers such as Minoxidil or Finasteride.

A user has been using finasteride since 2018, switched to dutasteride, and added minoxidil, microneedling, and a tretinoin/spiro compound. They are pleased with the results and hopeful for more improvement.

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.

OP injured their temple using derma rolling and tretinoin, causing peeling and potential hair follicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.

Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.

Before getting a hair transplant, it's crucial to research and understand that ongoing treatments like finasteride, dutasteride, or minoxidil are necessary to maintain results. Concerns were raised about Turkish clinics, including overharvesting grafts, lack of regulations, and discouraging finasteride use.